The 14th Congress on SLE & The 6th CORA Congress JOINT VIRTUAL EVENT





6-9 October 2021

lupus2021.kenes.com



LUPUS 2021 Abstract Awards

The LUPUS Scientific Organizing Committee would like to recognise the following six outstanding abstracts submitted to LUPUS 2021

With our congratulations,

Prof. Andrea Doria, Prof. Marta Mosca, Prof. Angela Tincani, Prof. Marcello Govoni

To read the abstracts, please visit the Poster Gallery in the Virtual platform





Awarded to Christian Lundtoft



IN RECOGNITION OF OUTSTANDING WORK ON THE ABSTRACT:

COMPLEMENT C4 COPY NUMBER VARIATION IS ASSOCIATED WITH ANTI-RO/SSA AND ANTI-LA/SSB AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS

About the Author:

I'm a researcher at the Department of Medical Sciences at Uppsala University, Sweden. My work focus on immunogenetics of autoimmune diseases, and I have a special interest in the genetic regulation of immunity-related signalling pathways, and in resolving the genetics of the complex HLA region.





Awarded to

Sara Dyball



IN RECOGNITION OF OUTSTANDING WORK ON THE ABSTRACT:

EARLY RISK OF INFECTION IN SLE PATIENTS TREATED WITH RITUXIMAB: RESULTS FROM THE BILAG-BIOLOGICS REGISTER

About the Author:

Sarah Dyball is an MRC funded clinical research fellow and rheumatology trainee presently undertaking her PhD at the University of Manchester supervised by Prof Ian Bruce and Dr Ben Parker. Her research aims to shift focus from describing patients by clinical phenotype to stratifying using immune pathways and shared biomarkers across connective tissue diseases.





Awarded to

Elena Carnero-Montoro



IN RECOGNITION OF OUTSTANDING WORK ON THE ABSTRACT:

MOLECULAR SUBTYPES, AUTOANTIBODIES PROFILES, GENDER AND GENETICS INFLUENCE THE EPIGENOME OF SYSTEMIC LUPUS ERYTHEMATOSUS

About the Author:


Postdoctoral researcher specialised in Genetic Epidemiology at GENyO, Granada, Spain, at Alarcón-Riquelme Group. Her research is focused on studying the (epi)genomic basis of systemic autoimmune diseases and on identifying genetic and environmental factors involved in epigenomic changes. She is part of international collaborative efforts such as 3TR, GoDMC, CHARGE consortium and PRECISESADs. Former research associate at King's College of London and ErasmusMC, Rotterdam.





Awarded to

Andrea Fava



IN RECOGNITION OF OUTSTANDING WORK ON THE ABSTRACT:

IL-16 IS LINKED TO LUPUS NEPHRITIS ACTIVITY

About the Author:

• Dr. Andrea Fava is a physician-scientist in the Division of Rheumatology. Dr. Fava's research is focused on lupus nephritis. As an Accelerating Medicines Partnership investigator, Dr. Fava is pursuing the discovery of novel (treatable) mechanisms and noninvasive biomarkers of lupus nephritis (liquid biopsy) using multiomic approaches such as single cell transcriptomics and urine proteomics. Dr. Fava is a faculty member of the Hopkins Lupus Center where he is involved in the care of patients with systemic lupus erythematosus (SLE) and lupus nephritis.





Awarded to

Md Yuzaiful Md Yusof



IN RECOGNITION OF OUTSTANDING WORK ON THE ABSTRACT:

COMPREHENSIVE GENETIC AND FUNCTIONAL ANALYSES OF FC GAMMA RECEPTOR IN DICTATING RITUXIMAB RESPONSE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

About the Author:

Dr. Md Yusof PhD is a Wellcome Trust ISSF Senior Research Fellow within the Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Consultant Rheumatologist at the Leeds Teaching Hospitals NHS Trust. His research works have focussed on B cell biology and therapies, SLE, Sjogren's, Pre-Connective tissue disease, personalised medicine and clinical trials.





Awarded to

Ronald van Vollenhoven



IN RECOGNITION OF OUTSTANDING WORK ON THE ABSTRACT:

BIIB059 DEMONSTRATES IMPROVEMENT IN JOINT MANIFESTATIONS IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE PHASE 2 LILAC PART A STUDY

About the Author:

Ronald van Vollenhoven is Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam University Medical Centers and Director of the Amsterdam Rheumatology and Immunology Center in Amsterdam, the Netherlands. Professor Van Vollenhoven's research focusses on the development and systematic evaluation of biological and immunomodulatory treatments for rheumatic diseases. With his coworkers, he established the Stockholm registry for biological therapies, which supported research projects relating to clinical efficacy, pharmacology, outcomes, and pharmacoeconomics. He has been Principal Investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to several important investigator-initiated trials including the SWEFOT, ADMIRE, and DOSERA trials.



The 14th Congress on SLE & The 6th CORA Congress JOINT VIRTUAL EVENT





lupus2021.kenes.com